By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year? - 2King Charles shares cancer treatment update, says it's a 'personal blessing'
- 3Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- 4Tehran defends ship seizure as a legal action, but tensions continue in the Gulf
- 5Shrapnel hits across central Israel, injuring several, causing property damage
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- Am I a Summer, or is this a scam? What I learned from color analysis.
- 5 Home EV Chargers for Proficient and Solid Charging
- Figure out How to Establish a long term connection with Your Handshake
- Crew-11 astronauts undock in 1st-ever medical evacuation from the International Space Station (video)
- Instructions to Expand Your Advantages from an Open Record Reward
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- What you need to know about flu treatments as cases spike across the US
